Short Summary
The dispute centered on whether Natco Pharma Limited (Natco) and Alembic Pharmaceuticals Ltd. could export products covered by compulsory licenses, specifically SORAFENAT/SORAFENIB, for regulatory development purposes outside India. Bayer challenged these exports, arguing they infringed the patent or violated the terms of the Compulsory Licence. The court ultimately held that non-patentee companies cannot be deprived of exercising rights under Section 107A merely because a compulsory license was granted.
Detailed Summary
When a patent holder loses control of the Indian market through a compulsory license, do they also get to dictate what happens beyond India's borders? That was the central tension in a high-stakes pharmaceutical dispute where a global innovator tried to use a domestic compulsory license as a shield against generic competition preparing for overseas regulatory approval.
Bayer Intellectual Property GmbH held the patent for SORAFENIB, marketed in India as SORAFENAT. The drug, used in oncology, became the subject of a compulsory license granted to Natco Pharma Limited, allowing domestic manufacture under specific conditions. Alongside Natco, Alembic Pharmaceuticals Ltd. also sought to operate in this space. The dispute arose when Alembic, along with Natco, sought to export products covered by the compulsory license for the purpose of regulatory development outside India. Bayer pushed back, arguing that such exports infringed its patent rights or violated the terms of the compulsory license framework.
Bayer's argument centered on the idea that once a compulsory license had been granted, the rights flowing from that license were tightly controlled, and any export activity by non-patentees for regulatory purposes fell outside the permitted scope. In essence, Bayer contended that the compulsory license regime should restrict how generic manufacturers could leverage the patented invention, even for legitimate preparatory activities abroad. On the other side, Alembic and Natco argued that Section 107A of the Patents Act independently protects acts done for regulatory approval, and this statutory right cannot be taken away simply because a compulsory license exists. The legal friction was clear: does a compulsory license override the Bolar-style exemption, or do these two legal frameworks coexist?
The court ruled in favor of the defendants, holding that non-patentee companies cannot be deprived of exercising their rights under Section 107A merely because a compulsory license has been granted. The court drew a clear distinction between the rights conferred by a compulsory license and the independent statutory right to make, construct, use, sell, or export a patented invention solely for purposes of regulatory approval. The compulsory license and the Section 107A exemption were treated as separate legal mechanisms, and the existence of one did not extinguish the other.
For founders and IP professionals in the pharmaceutical space, this case is a critical reminder: a compulsory license narrows the patentee's commercial monopoly in India, but it does not create a fortress around export activities tied to regulatory submissions. Generic manufacturers and startups developing bioequivalent or alternative formulations should understand that Section 107A rights survive independently of compulsory licensing decisions. Conversely, patent holders should not assume that a compulsory license gives them leverage to block all ancillary activities by competitors. The lesson is to map every statutory right separately, because in IP law, one provision's limits rarely bleed into another's protections.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court. Understanding the court's reasoning in Bayer Corporation vs Union of India is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
The North Face Apparel CorpvsController of Patents and Designs
The North Face Apparel Corp challenged the Controller of Patents' refusal of its patent application (No. 202147026139) titled 'Systems and Methods for End-to-End Article Management' before the Madras High Court under Section 117A of the Patents Act, 1970. The Controller had rejected the application citing lack of inventive step over prior art documents D21-D24. The Court held that the Controller erred by dissecting the claims into isolated elements rather than assessing the invention as a whole, and overlooked the use of spectrophotometer and invisible markers for tracking the manufacturing process, which were not disclosed in the cited prior art. The appeal was allowed and the Controller was directed to grant the patent.
Aventose Energy Private LimitedvsThe Assistant Controller of Patents & Designs, Patent Office Chennai
Aventose Energy Private Limited appealed under Section 117A of the Patents Act, 1970 against the refusal of its patent application (No. 202141019671) for a 'System and Method for Operating Automobiles with an Electric Drivetrain' featuring safe mode activation upon fault detection. The Madras High Court found that the Assistant Controller had contradicted the First Examination Report (which accepted novelty) by subsequently holding the invention lacked novelty without giving the applicant an opportunity to be heard. The court further held that the Controller improperly conflated novelty with inventive step under Section 2(1)(ja) and failed to properly analyze the claims against prior art documents D1–D4.
Apex Laboratories Pvt LtdvsElder Lifescience and Ambico Ayurvedic Health Care
Apex Laboratories Pvt Ltd, the prior adopter and registered proprietor of the trademark ZINCOVIT (TM No. 487453 in Class 5) since 1988, sought interim injunction against Elder Lifescience and Ambico Ayurvedic Health Care for using the deceptively similar mark NEO ZINCOVIT. The applicant also claimed copyright infringement of its registered artistic works (A-108878/2014) covering colour scheme, get-up, and layout. The Madras High Court was satisfied that the respondents were attempting to piggyback on the applicant's goodwill and granted interim injunctions on all three applications covering trademark infringement, copyright infringement, and passing off.
Radico Khaitan LimitedvsPicadilly Agro Industries Limited
This Special Leave Petition arose from a judgment dated 29-05-2026 in CS No. 8/2025 passed by the District Judge, Karnal, Haryana, concerning a trademark dispute over the marks 'Cashmere' and 'Kashmyr' used in relation to beer and vodka. The Supreme Court noted that a First Appeal (FAO-COM-11-2026) was already pending before the Division Bench of the Punjab and Haryana High Court, listed for 28.10.2026. The Court disposed of the SLP without adjudicating it on merits, requesting the High Court to pass an appropriate order regarding the ad interim injunction on the scheduled date.
Maharaja Agrasen Technical Educational Society (Regd.)vsMaharaja Agrasen Himalayan Garhwal University
The plaintiff, Maharaja Agrasen Technical Educational Society, filed a suit for permanent injunction against the defendant, Maharaja Agrasen Himalayan Garhwal University, alleging infringement and passing off regarding the use of the words 'Maharaja Agrasen' in the defendant's name. The Delhi High Court had previously granted a restraint order on 10.07.2026. During the pendency of the suit, the parties arrived at a settlement dated 14.09.2026, under which the defendant agreed to change its name through a statutory amendment while being permitted limited transitional use of its existing name. The court recorded the settlement, modified the interim order accordingly, and listed the matter for compliance reporting on 13.07.2027.
Varahi Diamonds And Finance LimitedvsSahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr.
This is a commercial suit filed by Varahi Diamonds And Finance Limited against Sahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr. before the Delhi High Court. The order is primarily procedural, dealing with the registration of the plaint, issuance of summons, directions for filing pleadings, and an interim injunction application. The matter was referred to mediation, with parties directed to appear before the Delhi High Court Mediation and Conciliation Centre.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.